Clinical Research Program

Endometriosis Studies

Endometriosis Study with 6 Month Commitment

Sponsor: Merck

Study Description

This study is testing an investigational non-hormonal medication, called MK-7264, to see if it is safe and effective in reducing moderate to severe endometriosis-related pelvic pain. The study will also evaluate the investigational medication’s tolerability, which refers to how the body handles the investigational medication and whether its potential benefits outweigh its side effects. In this study, MK-7264 will be compared to placebo. A placebo is something that looks like the investigational medication but does not contain any active medicine. In this study, you have a 1 in 2 chance of getting placebo only. Additionally, no matter which study drug you receive, you will also be given naproxen sodium to be used as a “rescue” medication for endometriosis-related pelvic pain, if needed.

Purpose of the Study

Research Study currently evaluating an oral investigational medication to see if it may reduce moderate to severe endometriosis-associated pain.

Eligibility

You may qualify to participate if you:

  • Are premenopausal, 18-49 years old
  • Have had a surgical diagnosis of endometriosis within the past 10 years
  • Have moderate to severe pain due to endometriosis during most recent menses and while off menses
  • Are not pregnant or actively trying to get pregnant
  • Do not have osteoporosis or any bone disease

Commitment

This study has a commitment duration of 24 weeks with 7 visits.

Compensation

If you qualify and decide to participate, you may receive up to $650.00 if all scheduled visits are completed.

Contact Information

To learn more or see if you qualify, call 804-920-0819

Endometriosis Study with 9 Month Commitment

Sponsor: Myovant

Study Description

The purpose of this study is to test how effective and safe the investigational study drug, relugolix (rel-U-GO-lix), given with or without low-dose estradiol and norethindrone is in treating your condition, endometriosis-associated pain. Estradiol is a form of estrogen and norethindrone is form of progesterone. The use of this FDA approved medication together with relugolix to treat patients with endometriosis-associated pain is investigational. You have been asked to take part in the study because your endometriosis was seen (for example, during a surgery) within the last 10 years and you are experiencing endometriosis-associated pain.  About 600 women around the world will take part in this study. We want to find how endometriosis pain affects how you function and feel and if the study drug is effective at treating the pain from your endometriosis.  You have a 2 in 3 chance of being placed in one of the groups that receives relugolix and a 1 in 3 chance of receiving an inactive pill (placebo). Pain medications will be prescribed as needed for endometriosis-related pelvic pain.

Purpose of the Study

Research Study currently evaluating an oral investigational medication to see if it may reduce moderate to severe endometriosis-associated pain.

Eligibility

You may qualify to participate if you:

  • Are premenopausal, 18-50 years old
  • Has regular menstrual cycles
  • Have had a surgical diagnosis of endometriosis within the past 10-12 years
  • Have moderate to severe pain due to endometriosis during most recent menses and while off menses
  • Are not pregnant or actively trying to get pregnant
  • Do not have osteoporosis or any bone disease

Commitment

This study has a commitment duration of 9 months with 9 scheduled visits.

Compensation

If you qualify and decide to participate, you may receive up to $1,725.00 if all scheduled visits are completed.

Contact Information

To learn more or see if you qualify, call 804-920-0819